Laserwelt, Verisante in non-invasive optical system distribution agreement

Laserwelt has entered into an agreement to distribute Verisante Technology’s non-invasive optical system, designed for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma.

Continue reading here:
Laserwelt, Verisante in non-invasive optical system distribution agreement

Tags: basal, carcinoma, cell, lesions, melanoma, qd-syringe, qdss, result, system

This entry was posted on Monday, January 14th, 2013 at 9:45 am by admin and is filed under Needlestick Statistics, Syringes. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.